Chronic kidney disease (CKD) is associated with increased risk of cardiovascular disease (CVD) and it is especially common among Blacks. Left ventricular hypertrophy (LVH) is an important subclinical marker of CVD, but there are limited data on racial variation in left ventricular structure and function among persons with CKD.
Chronic kidney disease (CKD) affects over 15 million Americans, and the prevalence has increased significantly over the last 3 decades. 1 CKD increases the risk for a broad range of cardiovascular diseases (CVD) and all-cause mortality. [2] [3] [4] [5] Left ventricular hypertrophy (LVH), a subclinical marker of CVD, is associated with shorter cardiovascular event-free survival, higher risk of incident heart failure, and higher risk of death among persons with CKD. [5] [6] [7] [8] Increases in left ventricular mass occur either via predominant wall thickening or predominant chamber enlargement that lead to concentric hypertrophy or eccentric hypertrophy. Concentric remodeling is defined as left ventricular wall thickening in the absence of significant increase in left ventricular mass. In contrast to Whites, Blacks may be predisposed to concentric hypertrophy, independently of blood pressure. 9 In the general population, higher prevalence of LVH and concentric hypertrophy among Blacks compared to Whites likely contributes to their increased risk of CVD and death. [9] [10] [11] [12] Studies in nondialysis dependent CKD patients vary with regard to racial/ethnic risk differences for occurrence of CVD events, CVD mortality, and all-cause mortality. [13] [14] [15] [16] [17] [18] [19] Several, small studies have examined differences in left ventricular geometry as explanatory factors. 20 We analyzed data from the Chronic Renal Insufficiency Cohort (CRIC) Study-a large, prospective, observational cohort study of men and women (45% non-Hispanic Whites and 46% non-Hispanic Blacks) with mild-to-moderate CKD 21 -to determine whether Blacks have a higher prevalence of concentric hypertrophy than Whites, and if Black race/ethnicity would be associated with increased risk for concentric hypertrophy independent of traditional CVD risk factors.
METHODS

Study design and participants
We conducted cross-sectional analyses among non-Hispanic Black and non-Hispanic White participants in the CRIC study. The design, methods, and baseline characteristics of the CRIC study have been previously published. 21, 22 In brief, the CRIC study is an ongoing prospective study of men and women between 21 and 74 years of age with mildto-moderate CKD, as defined by aged-based estimated glomerular filtration rate (eGFR) entry criteria (range 20-70 ml/min/1.73 m 2 ). Participants were recruited at 7 centers across the United States between May 2003 and March 2007. 22 Additional Hispanic participants were enrolled from October 2005 to June 2008 at a single CRIC Study site for a total of 3,939 participants (including 1,650 nonHispanic Black participants and 1,638 non-Hispanic White participants). 23 Our analytic sample included the 2,319 participants (1,164 non-Hispanic Black and 1,155 non-Hispanic White) with echocardiograms performed 1 year after enrollment and whose left ventricular mass index (LVMI) and relative wall thickness (RWT) could be determined. Informed consent was obtained from all participants.
Variables and measurements
We analyzed self-reported sociodemographics, medical history, lifestyle behaviors, and current medication use, blood pressure and anthropometric measurements (height, weight, and waist circumference) at the first annual followup visit, the time point at which the echocardiogram was performed. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of any antihypertensive medications. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Diabetes was defined as fasting glucose ≥126 mg/dl, random glucose ≥200 mg/dl, or use of insulin or diabetic medication. Glomerular filtration rate was estimated with a study-derived equation. 24 Transthoracic echocardiography was performed on CRIC participants at the year 1 visit using American Society of Echocardiography established protocols for M-mode, 2-dimensional, and Doppler echocardiography. 25 Left ventricular mass was calculated using 2D images of the left ventricular short axis muscle area and the apical left ventricular length. LVMI was calculated as left ventricular mass in g/height in m 2.7 , a measure thought to be more accurate among persons with CKD. 25, 26 Based on prior studies in patients with CKD, we defined LVH as LVMI >50 g/m 2.7 in males and >47 g/m 2.7 in females. 23, [26] [27] [28] RWT was calculated as 2 × posterior wall thickness/left ventricular internal end diastolic diameter. We defined increased RWT as ≥0.45. We used LVMI and RWT to categorize left ventricular geometry as: (1) normal (normal LVMI and RWT), (2) concentric remodeling (normal LVMI and increased RWT), (3) eccentric hypertrophy (increased LVMI and normal RWT), or (4) concentric hypertrophy (increased LVMI and RWT). Left ventricular cavity volumes were calculated using the modified biplane method, and ejection fraction was calculated using Simpson's method of disks. 25 Diastolic function was assessed by mitral inflow E-and A-wave velocities, E-wave deceleration time, and pulmonary venous reverse A-wave duration and categorized as normal or abnormal relaxation (mild, moderately, or severe) using established criteria. 29 
Statistical analysis
We analyzed sociodemographic characteristics, clinical data, and echocardiographic measurements using SAS statistical software (version 9.4; SAS, Cary, NC). For continuous variables, we calculated the mean value and SD or median value and interquartile range. We summarized dichotomous variables as frequencies and proportions. We performed descriptive statistical testing with 2-sample t tests, Wilcoxon rank-sum test, and Pearson's Chi squared, and defined significance as P < 0.05.
We generated 2 multiple regression models. In the first model, we used multiple linear regression to model LVMI as a continuous outcome measure. In the second, we used multivariable multinomial logistic regression to simultaneously identify correlates of concentric hypertrophy, eccentric hypertrophy, and concentric remodeling vs. normal left ventricular geometry in a single model. We selected candidate variables based on literature review, input from CRIC investigators, and the results of univariate analyses of left ventricular remodeling. Black race/ethnicity was the primary exposure of interest. Other variables included in the linear regression model were age, sex, history of diabetes, history of myocardial infarction or revascularization, history of peripheral artery disease, history of heart failure, current smoking, SBP, eGFR, hemoglobin, total parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and serum phosphate. Due to the small number of measurements of phosphate, PTH, and FGF23 levels at the first follow-up visit, we carried forward the values from participants' baseline visit in our analyses. We also included in the model selfreported use of more than 3 antihypertensive medications as a marker of hypertension severity and 24-hour urinary protein as an additional marker of CKD severity. We did not include hypertension as a categorical variable because the prevalence was approximately 90% in our sample. We did not include BMI in the primary analysis due to collinearity with the LVMI, which is measured in g/m 2.7 . We transformed selected variables to satisfy the assumptions of normality and constant variance. We tested for interactions between race/ethnicity and SBP. For the multinomial logistic regression model, we used the same variables as in the linear regression analyses.
Sensitivity analyses
We conducted 3 sensitivity analyses. First, we restricted the sample of participants to those who did not report a no prior history of heart failure. Second, we restricted the sample of participants to those with a left ventricular ejection fraction >50%. Third, we added BMI as a covariate in the models from the primary analysis to see if it attenuated the association between race/ethnicity and the outcomes of interest.
RESULTS
Characteristics of the 2,319 participants (1,164 non-Hispanic Black and 1,155 non-Hispanic White) who completed year 1 visits with echocardiograms and measured LVMI and RWT are presented in Table 1 . Their mean age of the study population was 58.8 ± 10.7 years, and 53.3% were male. Compared to non-Hispanic Whites, non-Hispanic Blacks had higher prevalence of diabetes (51.0% vs. 38.2%; P < 0.0001), hypertension (95.3% vs. 81.3%; P < 0.0001), pre-existing heart failure (14.6% vs. 7.0%; P < 0.0001), and tobacco use (17.8% vs. 8.7%. P < 0.001).
Compared to non-Hispanic White participants, nonHispanic Blacks had higher mean BMI, lower mean eGFR, higher median proteinuria, higher mean hemoglobin A1C, lower hemoglobin, and higher median FGF23 levels (all P < 0.05). Non-Hispanic Blacks reported greater use of antihypertensive medications and had higher mean SBP and diastolic blood pressure (P < 0.0001).
Left ventricular structure and function differed significantly between non-Hispanic Blacks and non-Hispanic Whites. Non-Hispanic Blacks had higher mean LVMI than Whites (54.7 ± 14.6 vs. 47.4 ± 12.2 g/m 2.7 ; P < 0.0001) and a higher prevalence of LVH (61.6% vs. 38.7%; P < 0.0001) ( Table 2) . Non-Hispanic Black participants also had higher prevalence of diastolic and systolic dysfunction and larger left ventricular end diastolic volume (P for all comparisons <0.05).
Compared to non-Hispanic Whites, non-Hispanic Blacks had a higher unadjusted prevalence of any type of abnormal left ventricular geometry (87.9% vs. 70.1%; P < 0.001). NonHispanic Blacks and Whites differed in the distribution of left ventricular geometric patterns (P < 0.0001) (Figure 1 ). Compared to non-Hispanic Whites, non-Hispanic Blacks had a higher prevalence of concentric LVH (45.8% vs. 24.9%) and eccentric LVH (15.8% vs. 13.9%). Non-Hispanic Whites had a higher prevalence of concentric remodeling; however, this was in the setting of a higher prevalence of normal left ventricular geometry and the lower prevalence of LVH.
Multivariable linear and logistic regression analyses
In multivariable linear regression analysis, Black race/ ethnicity was associated with higher LVMI (Table 3) . Twelve other variables were significantly associated with higher LVMI, including older age, male sex, self-reported use of more than 3 antihypertensive medications, higher SBP, prevalent diabetes, prevalent CVD (peripheral artery disease, prior myocardial infarction or revascularization, heart failure), lower hemoglobin, significant proteinuria, and higher FGF23 and PTH levels. Table 4 summarizes the multinomial logistic regression analysis of the odds for concentric hypertrophy, eccentric hypertrophy, and concentric remodeling vs. normal left ventricular geometry. Black vs. White race/ethnicity was associated with higher odds for concentric LVH (odds ratio [OR] = 2.73, 95% confidence interval [CI]: 2.02, 3.69). Markers of the hypertension severity-self-reported use of more than 3 antihypertensive medications (OR = 2.10, 95% CI: 1.48, 2.98) and higher SBP (OR = 1.02, 95% CI: 1.01, 1.03)-were also associated with higher odd ratios for concentric hypertrophy; however, these markers of hypertension severity were not associated with a higher odds ratio for concentric remodeling. Other variables associated with higher odds of concentric LVH include older age, absence of diabetes, higher FGF23, lower eGFR, and higher PTH. Black vs. White race/ethnicity was also associated with higher odds for concentric remodeling (OR = 2.16, 95% CI: 1.61, 2.90) and for eccentric hypertrophy (OR = 1.81, 95% CI: 1.27, 2.58).
Sensitivity analyses
In the sensitivity analysis restricted to participants without a history of heart failure, Black race/ethnicity remained independently associated with higher LVMI (P < 0.001), and higher odds for concentric hypertrophy (OR = 2.82, 95% CI: 2.05, 3.87), eccentric hypertrophy (OR = 1.65, 95% CI: 1.12, 2.43), and concentric remodeling (OR = 2.13; 95% CI: 1.58, 2.89). In the sensitivity analysis restricted to those with a left ventricular ejection fraction >50% and the analysis that included BMI as a covariate, the association between Black race/ethnicity and higher LVMI and abnormal cardiac remodeling remained significant (data not shown).
DISCUSSION
In a large cohort of men and women with mild-to-moderate CKD, we found that the prevalence of LVH among nonHispanic Black participants was approximately 1.6 times (61.6% vs. 38.7%) higher than non-Hispanic White participants. Concentric hypertrophy was over 1.8 times (45.8% vs. 24.9%) more prevalent in non-Hispanic Black than non-Hispanic White participants. Non-Hispanic Blacks were significantly more likely to have diastolic and systolic dysfunction and increased left ventricular end diastolic volume than nonHispanic Whites. In other studies, the prevalence of LVH in CKD patients ranges from 16% to 74%; however, none of these studies directly compared large samples of non-Hispanic Black and non-Hispanic White CKD patients. 6, 20, [30] [31] [32] [33] [34] At baseline, CRIC non-Hispanic Black participants with CKD had a greater prevalence of comorbidities and clinical and laboratory markers of CKD severity than non-Hispanic White participants. Many of these characteristics are known to contribute to cardiac hypertrophy. In adjusted analyses, Black race/ethnicity remained independently associated with higher LVMI, 2.7 times higher odds for concentric LVH, and 1.8 higher odds for eccentric hypertrophy, and 2.2 times higher odds for concentric remodeling. The results were qualitatively unchanged when we restricted the analyses to individuals without a prior history of heart failure and with a left ventricular ejection fraction >50%. The persistent association between race/ethnicity and left ventricular remodeling in the adjusted model suggests that other factors beyond cardiovascular risk factors, such as genetic factors, volume load, neurohormonal milieu, extracellular matrix alterations, and other comorbidities, 9 may contribute to the higher prevalence of LVH and difference in type of left ventricular remodeling between Blacks and Whites.
Studies that compared differences in risk for CVD outcomes and death for Blacks and Whites with CKD reported conflicting results. [13] [14] [15] [16] [17] [18] [19] A pooled analysis from 4 cohorts found a higher risk of CVD events and death for Blacks than Whites, 13 while a recent CRIC analysis reported a lower risk of death or atherosclerotic event in Blacks than Whites in an adjusted model. 16 Studies in CRIC and in the Multi-Ethnic Study of Atherosclerosis found that the higher risk for heart failure in Blacks than in Whites is largely related to differences in CVD risk factors and socioeconomic status. 16, 35 However, these analyses did not examine the relationship between race/ ethnicity, left ventricular geometry, and CVD outcomes. In the general population, studies have shown that differences in left ventricular geometry likely contribute to the differences in CVD outcomes between Blacks and Whites. [9] [10] [11] [12] Our findings suggest that CVD risk factors alone cannot account for the higher odds concentric hypertrophy, eccentric hypertrophy, and concentric remodeling among Black and Whites in the presence of CKD. Thus, further research in understanding the relationship between race/ethnicity and left ventricular geometry on CVD outcomes in CKD patients is needed.
In support of our results, many of the identified correlates of left ventricular remodeling, such as higher serum FGF23 levels, higher serum phosphate levels, and lower eGFR, are consistent with prior studies of LVH and concentric hypertrophy in the general population and in patients with CKD, including analyses in CRIC. 9, 27, 36 Our findings also underscore the importance of the relationship between the level of blood pressure and LVH. In our regression models, higher SBP and hypertension severity, measured by use of more than 3 antihypertensive medications, were each positively associated with higher LVMI, eccentric hypertrophy, and concentric hypertrophy.
Our study has a number of strengths. They include a large number of Blacks-a historically underrepresented Black population in large, CKD cohorts-and the consideration of a relatively large number of cardiovascular risk factors. There are also several limitations. Our findings should be interpreted in light of the cross-sectional design, which limits our ability to infer causation. We selected covariates based on literature review, author expertise, and univariate analyses. We used baseline values of phosphate, FGF23, and total PTH measurements in the regression model instead of values from the 1-year follow-up visit due to data availability. The relationship between vitamin D levels, troponin T, N-terminal pro-B-type natriuretic peptide, inflammation, and left ventricular remodeling in CKD patients has been previously investigated in CRIC 28, [37] [38] [39] [40] ; however, these variables were not included in our regression models. Unmeasured variables may have confounded the multivariable models. This is the first large-scale demonstration of significant differences in left ventricular mass, hypertrophic morphology, and function between non-Hispanic Black and nonHispanic Whites in a racially balanced, US-based cohort of participants with mild-to-moderate CKD. Future, longitudinal studies will define the impact of differences in cardiac structure and function on risk for adverse cardiovascular event rates, cardiovascular mortality, and all-cause mortality between Black and White CKD patients.
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